Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs DAPT after LAAO (ESCORT-AF Study(B))
NCT04135677Phase 4Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Nov 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rivaroxaban in thrombosis, stroke, sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
thrombosisstroke
Beyond the preview
Go deeper on NCT04135677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04135677.